Enzo Biochem (NYSE:ENZ) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Enzo Biochem (NYSE:ENZ) in a research report sent to investors on Saturday. The firm issued a hold rating on the medical research company’s stock.

Enzo Biochem Trading Down 1.4 %

Shares of NYSE:ENZ opened at $0.66 on Friday. Enzo Biochem has a 1 year low of $0.63 and a 1 year high of $1.44. The firm’s 50-day moving average is $0.87 and its two-hundred day moving average is $1.04.

Enzo Biochem (NYSE:ENZ) last released its earnings results on Monday, December 16th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter. Enzo Biochem had a negative return on equity of 7.96% and a negative net margin of 75.34%.

Enzo Biochem Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 2nd. Shareholders of record on Friday, November 15th were issued a dividend of $0.10 per share. The ex-dividend date of this dividend was Friday, November 15th. This represents a $0.40 annualized dividend and a yield of 60.98%.

Institutional Investors Weigh In On Enzo Biochem

Hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd raised its holdings in shares of Enzo Biochem by 94.5% in the 2nd quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 13,735 shares in the last quarter. BBR Partners LLC acquired a new stake in Enzo Biochem in the third quarter valued at $112,000. Geode Capital Management LLC lifted its holdings in Enzo Biochem by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock worth $413,000 after buying an additional 11,742 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Enzo Biochem by 2.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock worth $2,725,000 after buying an additional 64,417 shares during the last quarter. Institutional investors and hedge funds own 36.90% of the company’s stock.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.